An updated guideline on pharmacotherapy of obesity management in adults includes six new and seven revised recommendations, reflecting the latest evidence through May 2025.
Canada has released an updated guideline on pharmacotherapy for obesity management in adults that includes six new and seven revised recommendations, reflecting the latest evidence through May 2025.Researchers conducted a systematic literature review from January 2022 to July 2024, supplemented by relevant trials published through May 2025, to identify studies assessing the efficacy of pharmacotherapy for weight management .
They also conducted 13 targeted searches on managing weight-related complications in 13 subpopulations with adiposity-related health issues, including cardiovascular disease, heart failure, prediabetes, obstructive sleep apnea, and osteoarthritis, among others.Measures of central adiposity, in addition to ethnicity-specific BMI and adiposity-related complications, should be used to guide the decision to initiate pharmacotherapy. Obesity pharmacotherapy should be used in conjunction with health behavior changes and individualized based on a person’s specific health needs, values, and preferences. The recommendations include two new medications, tirzepatide and setmelanotide, that were not included in previous versions of the guideline, as well as new recommendations for obesity-related complications. The researchers recommend against the use of compounded medications or medications other than those approved for weight loss in people with excess adiposity.Obesity pharmacotherapy “is one of three pillars of treatment outlined in the full Canadian Adult Obesity Clinical Practice Guideline, with other pillars being behavioral and psychological and surgical approaches,” said the author in a press release. “Obesity treatment should always be tailored to each person’s specific health needs, values, and preferences.”The study, led by Sue Pedersen, MD, endocrinologist and obesity medicine specialist in Calgary and lead author of the guideline, wasThe guideline has limitations, in that it includes only medications currently approved in Canada, although other medications are approved for obesity management in other countries. Also, there are more than 200 health complications associated with obesity, and it was not feasible to search the literature for all of them.Pedersen reported receiving grants for clinical trials from Novo Nordisk, AstraZeneca, Sanofi, Eli Lilly and Company, Boehringer Ingelheim, Prometric, and Pfizer, and consulting fees from AstraZeneca, Bausch Health, Eli Lilly and Company, Novo Nordisk, Janssen, Boehringer Ingelheim, Sanofi, Merck, Abbott, Dexcom, HLS, Bayer, AbbVie, Roche, Amgen, and Pfizer. She has also received payment for medical education lectures and speakers bureaus from AstraZeneca, Bausch, Eli Lilly and Company, Novo Nordisk, Janssen Pharmaceuticals, Boehringer Ingelheim, Sanofi, Merck, Abbott, Dexcom, HLS, Bayer, and Pfizer, and has received travel support from AstraZeneca, Bausch, Eli Lilly and Company, Novo Nordisk, Boehringer Ingelheim, Abbott, and Dexcom. In addition, Pedersen reported participating on a data safety monitoring board for Regeneron. The other coauthors also report receiving fees from multiple commercial entities. These competing interests are included in the paper. Marilynn Larkin, MA, is an award-winning medical writer and editor whose work has appeared in numerous publications, including Medscape Medical News and its sister publication MDedge, This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our‘Clinical Obesity’ Definition Shifts Obesity Prevalence
Obese Canada Canadian Clinical Guidelines Guidelines Obstructive Sleep Apnea Obstructive Sleep Apnea Syndrome Obstructive Sleep Apnoea Obstructive Sleep Apnoea Syndrome Heart Failure Heart Failure (HF) CV Risk Cardiovascular Risk CV Risk Factors Cardiovascular Risk Factors Cardiovascular Risk Management CV Risk Management Weight Management Artificial Intelligence
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Mariners beat MLB-leading Tigers 8-4, sweeping 3-game series before All-Star breakJorge Polanco and Cole Young hit back-to-back home runs in a four-run ninth inning and the Seattle Mariners beat the Detroit Tigers 8-4 on Sunday to complete a
Read more »
Cam Heyward rejects ‘king’ label in Steelers locker room amid sweeping changes for 2025 seasonThe 14-year vet mentors young players as Pittsburgh makes all-in moves with Aaron Rodgers, DK Metcalf & Jalen Ramsey.
Read more »
Apple's latest updates fix over 20 issues in iOS and nearly 80 in macOSIzzy, a tech enthusiast and a key part of the PhoneArena team, specializes in delivering the latest mobile tech news and finding the best tech deals. Her interests extend to cybersecurity, phone design innovations, and camera capabilities.
Read more »
Live updates: Trump blasts Canada and India on eve of deadline for trade dealsThis is additional taxonomy that helps us with analytics
Read more »
Donald Trump Issues Threat To Canada Over 'Statehood of Palestine' MovePresident Donald Trump says Canada's support for a Palestinian state will make any trade deal between Washington and Ottawa 'very hard.'
Read more »
Keep Canada’s Health Data Safe and in Canada, Experts SayThe need to keep Canada’s health data secure and independent is urgent, especially in today’s changing political climate, but differences exist on how to achieve those goals.
Read more »